Listen to Dr. Isaac Garcia-Murillas from The Institute of Cancer Research and Dr. Richard Chen, CMO and EVP of R&D, Personalis, discuss a study with leading world experts in breast cancer (Dr. Nicholas Turner from The Royal Marsden NHS Foundation Trust) highlighting how NeXT Personal® was able to detect the smallest traces of cancer in the blood (ctDNA) a median of ~15 months ahead of scans in a cohort of 78 patients with breast cancer (all subtypes). In this robust study, median follow-up time was ~6 years and researchers analyzed 619 plasma samples (a median of 8 samples per patient). Learn about the results of ultra-sensitive MRD testing with NeXT Personal in Breast Cancer. #PrecisionOncology #LiquidBiopsy #MRD #ctDNA #BreastCancer #BreastCancerAwarenessMonth
Personalis, Inc.
Biotechnology Research
Fremont, California 22,932 followers
Personalizing Precision Oncology
About us
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California.
- Website
-
https://www.personalis.com/
External link for Personalis, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Fremont, California
- Type
- Public Company
- Founded
- 2011
- Specialties
- NGS, Immuno-oncology, Tumor Profiling, Tumor/Normal Analysis, Immunogenomics, Personalized Cancer Vaccines, Immune Modulators, Tumor Escape, Tumor Microenvironment, HLA Typing, Neoantigens, Whole Exome, Whole Transcriptome, Machine Learning, and Neural Networks
Locations
-
Primary
6600 Dumbarton Circle
Fremont, California 94555, US
Employees at Personalis, Inc.
Updates
-
Personalis, Inc. reposted this
“In a world where ultra-sensitive MRD does not exist, unfortunately, [this patient] would have most likely…gone on to relapse.” Dr. Georges Azzi, MD, Hematology and Oncology, from Holy Cross Health, shares his experience with caring for a patient with endometrial carcinoma. Using NeXT Personal® Dx, Dr. Azzi was able to detect ultra-low ctDNA post-surgery to inform the patient’s course of care, and, in real time, track the efficacy of treatment with ultra-precise ctDNA detection. Watch the video to learn more, and visit our website to discover more about NeXT Personal Dx: https://bit.ly/4cVfBJK. #PrecisionOncology #LiquidBiopsy #ctDNA #MRD
-
We had a wonderful time hosting BLOODPAC's Q3 in-person meeting last month! This event brought together industry leaders advancing the #LiquidBiopsy field for two days of dynamic discussion, meaningful collaboration, and some good fun! Huge thank you to all those who helped organize and lead a great event (Lauren C. Leiman, Dorys L., Cheyenne Jankiewicz, Matthew M., Dan Norton, MBA, Olga Alexeeva, Alvaro Rodriguez, Tara Andersen, Judith de Perio (Cooper), James Fink, Polo Alvarado, Francisco Escalante, Alan Duong, and many more). Check out the highlights below…
-
Personalis, Inc. reposted this
Almost a month since our Q3 meeting! In this clip Dan Norton, MBA from Personalis, Inc. and co-chair of our MRD Clinical Validation Working Group shares his takeaways on BLOODPAC’s Q3 meeting. Dan's key insight: in-person collaboration accelerates progress and offers a unique opportunity to witness the impressive work across other groups. It’s a great reminder of how teamwork drives innovation. 🙌 A big thank you to Dan and the rest of the team at Personalis, Inc. for hosting and facilitating collaboration among our working groups! #LiquidBiopsy #MRDclinicalvalidation
-
We’re in Basel for #BiomarkersEurope 2024! (Amanda Castle & Christelle Johnson, Ph.D.) Visit us at booth # 23. Check out a talk later today by Christelle Johnson, PhD, Associate Director, Field Applications Scientists, Personalis, highlighting several clinical case studies in lung and breast cancer utilizing NeXT Personal®, an ultra-sensitive liquid biopsy assay designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. #Biomarkers #PrecisionOncology #LiquidBiopsy #ctDNA #MRD #BreastCancer #LungCancer
-
Next week, our team will be in Basel, Switzerland for #BiomarkersEurope 2024! Visit us at booth 23. Want to meet with our team (Amanda Castle & Christelle Johnson, Ph.D.)? Reach out to us here: https://bit.ly/4goxSSO. Make sure to listen in to a talk by Christelle Johnson, PhD, Associate Director, Field Applications Scientists, Personalis, highlighting several clinical case studies in lung and breast cancer utilizing NeXT Personal®, an ultra-sensitive liquid biopsy assay designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. This talk will be in conference room 3 as part of the multi-cancer early detection techniques and companion diagnostics for precision oncology track. To date, we have 6 studies that have been presented pointing to the critical role of an ultra-sensitive MRD approach for identifying patients at risk for cancer recurrence, monitoring therapy response, and detecting cancer recurrence earlier. #Biomarkers #PrecisionOncology #LiquidBiopsy #ctDNA #MRD #BreastCancer #LungCancer
-
The U.S. Department of Veterans Affairs (VA) Million Veteran Program (MVP) is now one million Veterans strong! At Personalis, we’ve delivered over >180K whole-genome sequencing (WGS) samples for the VA MVP program, which is a national research program looking at how genes, lifestyle, military experiences, and exposures affect health and wellness in Veterans. We’re excited to announce our participation in “One Million Reasons,” a celebratory event honoring this momentous milestone in health research. Christopher Hall, CEO at Personalis, and Christian Haudenschild, PhD, SVP, Genomic Laboratory Services at Personalis, will be participating at the event next week on September 23rd, 2024 in Washington D.C. Dr. Haudenschild will be sharing key insights about the impact the MVP data has had on genetic research and understanding of genomics during a panel session, “How MVP has Changed the Game.” We look forward to celebrating this historic milestone with fellow researchers, industry leaders, MVP leaders, and Veterans. #PrecisionMedicine #Veterans #Genomics #NGS #Sequencing
-
At the European Society of Medical Oncology Congress (ESMO) Congress 2024 in Barcelona, Spain, we presented compelling data highlighting the performance of our NeXT Personal® assay, which was designed to detect and monitor residual and recurrent disease (MRD) in cancer patients by detecting very small traces of circulating tumor DNA (ctDNA) in the blood. Two studies were presented at ESMO further demonstrating the importance of using an ultrasensitive MRD assay to monitor lung cancer patients and patients on immunotherapy. Professor Charles Swanton and his colleagues at Cancer Research UK (CRUK), UCL (University College London) and The Francis Crick Institute analyzed over 400 non-small cell lung cancer (NSCLC) patients from their TRACERx lung cancer study, using the NeXT Personal assay. It represents one of the largest and most comprehensive MRD studies in lung cancer performed to date. These new results expand on and further strengthen the ground-breaking results of the initial study presented at last year’s ESMO congress: - Strong detection rates for residual lung cancer in the landmark period, the first 120 days after surgery - A high percentage of these landmark detections (42%) occur in the ultrasensitive range (less than 80 ppm) enabled by NeXT Personal - Pre-operative detections predict clinical outcome in lung adenocarcinoma, the most common type of lung cancer - Dynamic monitoring with NeXT Personal through adjuvant therapy can stratify patients for clinical outcome NeXT Personal demonstrated high sensitivity for detecting early-stage lung cancer recurrence with detection months ahead of imaging and the ability to identify low and high-recurrence risk patients before and after surgery. In the second abstract, Dr. Rodrigo Toledo, PhD MBA at the Vall d'Hebron Institute of Oncology (VHIO) presented data on a large cohort of over 200 late-stage cancer patients on immunotherapy profiled using the NeXT Personal assay, significantly expanding on the initial cohort first presented earlier this year. The study was unique in having a validation set of patients and it demonstrated that patients who had a significant decrease in ctDNA levels in response to immunotherapy had significantly longer overall survival than those who did not. Learn more from the press release: https://bit.ly/3Twpkz7. #PrecisionOncology #ESMO24 #TRACERx #LungCancer #Immunotherapy #ctDNA #MRD
-
We’re at #ESMO24! Stop by booth 509 to say hello and to learn more about our innovative solutions for oncology. Check out a poster today from one of our collaborators, Rodrigo Toledo, PhD MBA, from the Vall d'Hebron Institute of Oncology (VHIO). The poster (223P) highlights immunotherapy monitoring with NeXT Personal® in a phase 1 metastatic pan-cancer cohort. Want to get in touch at ESMO? Contact us: https://bit.ly/4goxSSO. #PrecisionOncology #Biomarkers #ctDNA #ImmunoTherapy
-
Insightful talk from one of our collaborators, Charles Swanton, at #ESMO24! Dr. Swanton highlighted new post-surgical monitoring data from the groundbreaking TRACERx study, one of the most robust ctDNA studies for early-stage non-small cell lung cancer (NSCLC). Visit us at booth # 509 to learn more about the data. Want to get in touch at ESMO? Contact us: https://bit.ly/4goxSSO. #PrecisionOncology #TRACERx #LungCancer #Biomarkers #ctDNA #ImmunoTherapy